Lung Cancer | Specialty

Current Management of Oncogene-Driven NSCLC

August 3rd 2020

The Evolving Treatment Landscape in SCLC

July 31st 2020

Beth Sandy, MSN, CRNP, discusses the evolving treatment landscape in small cell lung cancer.

Dr. Sabari on Biomarkers of Response to Immunotherapy in Advanced NSCLC

July 31st 2020

Joshua K. Sabari, MD, discusses the need for additional biomarkers of response to immunotherapy in driver-negative advanced non–small cell lung cancer.

FDA Grants Adjuvant Osimertinib Breakthrough Status in Early-Stage EGFR+ NSCLC

July 30th 2020

The FDA has granted a breakthrough therapy designation to osimertinib for the adjuvant treatment of patients with stage IB, II, and IIIA EGFR-mutated non–small cell lung cancer following complete resection with curative intent.

Navigating New Immune-Based Combinations in Advanced NSCLC

July 29th 2020

Joshua K. Sabari, MD, discusses a number of immunotherapy regimens that have emerged in the frontline setting for patients with driver-negative advanced non–small cell lung cancer; however, for many patients, the decision comes down to pembrolizumab monotherapy or pembrolizumab in combination with platinum-doublet chemotherapy.

Savolitinib Granted Priority Review in China for METex14+ NSCLC

July 28th 2020

Hutchinson China Meditech Limited announces that The China National Medical Products Administration granted priority review to the new drug application for the MET inhibitor savolitinib for the treatment of patients with non–small cell lung cancer with MET exon 14 skipping mutations.

Poziotinib Yields Positive Results in HER2 Exon 20 Insertion–Mutated NSCLC

July 28th 2020

The phase 2 ZENITH20 trial evaluating poziotinib in previously treated patients with non–small cell lung cancer and HER2 exon 20 insertion mutations met its prespecified primary end point.

Dr. Bunn on Data With Trastuzumab Deruxtecan in HER2-Mutant NSCLC

July 27th 2020

Paul A. Bunn, Jr, MD, highlights encouraging data with fam-trastuzumab deruxtecan-nxki in HER2-mutant non–small cell lung cancer.

Dr. Chiang on Unanswered Questions With Immunotherapy in NSCLC

July 27th 2020

Anne Chiang, MD, PhD, discusses unanswered questions with immunotherapy in non–small cell lung cancer.

Lara Shares Updates With Immunotherapy in Extensive-Stage SCLC

July 27th 2020

Although platinum-based chemotherapy given concurrently with a PD-L1 inhibitor has become the standard of care for the frontline treatment of patients with extensive-stage small cell lung cancer, investigators have found that maintenance immunotherapy and combination strategies have fallen short of expectations.

Osimertinib Results Show Potential for Earlier TKI Use in EGFR-Mutant NSCLC

July 27th 2020

The introduction of tyrosine kinase inhibitor therapy earlier in the treatment timeline for patients with EGFR-mutant non–small cell lung cancer holds the promise of improving overall survival for this patient population.

Gandara Reflects on Current Status of TMB in NSCLC

July 27th 2020

David R. Gandara, MD, discusses the current state of tumor mutational burden in lung cancer, ongoing research further examining the utility of this biomarker, and challenges to address with future research.

Talking KRAS-Targeted Therapy in NSCLC With Dr. Riess

July 27th 2020

In our exclusive interview, Jonathan W. Riess, MD, MS, discusses the excitement surrounding KRAS G12C inhibitors in non–small cell lung cancer, preliminary efficacy and safety data with AMG 510, and additional research regarding co-mutations and combinations that could lead to further refinement of the potential role of the agent in the landscape.

USPSTF Seeks To Expand Age, Pack-Year LDCT Screening Criteria

July 26th 2020

Under a draft recommendation proposed by the US Preventive Services Task Force, individuals who are at a high risk for developing lung cancer because of their smoking history would begin annual screening with low-dose computed tomography at age 50 rather than the current clinical standard of 55 years.

Dr. Reck on Safety Data From the CheckMate-9LA Trial in Metastatic/Recurrent NSCLC

July 24th 2020

Martin Reck, MD, PhD, discusses ​safety data from the ​phase 3 CheckMate-9LA trial in metastatic or recurrent non–small cell lung cancer.

Dr. Ramalingam on Next Steps With Nivolumab/Ipilimumab in NSCLC

July 24th 2020

Suresh S. Ramalingam, MD, FASCO, discusses the utility of nivolumab plus ipilimumab in metastatic or recurrent non–small cell lung cancer.

Dr. Baas on the Promise of Immuno-Oncology in Mesothelioma

July 24th 2020

Paul Baas, MD, PhD, discusses recent updates in immuno-oncology within the field of mesothelioma.

Dr. Levy on the Efficacy of Crizotinib Versus Entrectinib in ROS1+ Lung Cancer

July 24th 2020

Benjamin P. Levy, MD, discusses the efficacy of crizotinib (Xalkori) versus entrectinib in ROS1-rearranged lung cancer.

Dr. Shafique on the Goal of the CLASSICAL-Lung Trial With Pepinemab/Avelumab in NSCLC

July 24th 2020

Michael R. Shafique, MD, discusses the dose escalation and expansion of pepinemab in the phase 1b/2, single arm, first-in-human, CLASSICAL-Lung study in advanced non-small cell lung cancer.

Aggarwal Lends Insight on the Use of TKIs and Liquid Biopsies in ALK+ NSCLC

July 24th 2020

Charu Aggarwal, MD, MPH, discusses the current state of treatment for patients with ALK-positive non–small cell lung cancer, the utility of liquid biopsy, and remaining questions that need to be addressed in the space.